The effect of propranolol was studied in a double-blind crossover trial in 24 carefully selected hypertensive outpatients. Each patient received propranolol 60 mg/day, 120 mg/day, 240 mg/day, and placebo for four weeks each according to a randomised sequence. Propranolol 60 mg/day was no better than placebo in reducing blood pressure. The effects of propranolol 120 mg/day and 240 mg/day were not significantly different. Both doses reduced lying blood pressure by about 20/10 mm Hg from an initial level of 173/104 mm Hg. No difference was detected between the effects of the different doses of propranolol and placebo on weight or on the occurrence of adverse reactions.
Introduction
Propranolol is the most widely used beta-adrenoceptor antagonist in the treatment of hypertension and has been available for 11 years. Nevertheless, the optimum dosage regimen has not been established, and although incremental dosage studies have been carried out we have been unable to trace a within-patient crossover study that compares the effects of different doses in hypertensive patients. We report a controlled assessment of oral propranolol at three doses (60, 120, 240 mg/day) Conduct of outpatient trial-After discharge from hospital the patients were seen at the hypertension clinic within two weeks. The design used was identical to that used in a previous study to assess the efficacy of practolol.1 A double-blind crossover method was used to assess the effects on lying, standing, and postexercise blood pressure ofthe following four treatments, each provided by two identical-looking tablets and given thrice daily: (a) propranolol 20 mg; (b) propranolol 40 mg; (c) propranolol 80 mg; (d) placebo. Each treatment was given for four weeks and each patient received the four treatments. The order of administration was determined by a random code that ensured that each of the 24 possible permutations of four treatments was given to one of the 24 patients. Thus each treatment period followed or preceded any other treatment period on six occasions. Four-week supplies of drugs were given to each patient in prepacked and paired containers. The conduct of the trial and the statistical techniques used were identical to those described in the accompanying paper.
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66-5 ± 05 1 66-0± 071 65-6 ± 051 65-6 ± 07 in mind when examining individual treatment comparisons of these variables. The effects of 120 mg/day and 240 mg/day differed little, if at all. The effects of 60 mg/day were not significantly different from those of placebo. The pulse rate results for the propranolol periods were all significantly different from those for the placebo period. There were no significant differences between the effects of the different doses of propranolol on weight.
Analysis of the questionnaire on side effects showed similar patterns with each dose and with placebo. No dose-related adverse reactions were detected. 
SINGLE-DOSE INPATIENT STUDY
Analysis of the mean levels of lying and standing systolic and diastolic blood pressure showed a significant reduction in mean lying diastolic blood pressure levels at 30, 60, 90, 120, and 240 minutes with the single 80-mg (13 patients) dose of propranolol over the four-hour period of observation (table III) . 
Discussion
The results show that in a within-patient comparison of doses oral propranolol 120 mg/day was as effective in lowering blood pressure levels as 240 mg/day. A reduction of about 20/10 mm Hg was achieved from a mean initial lying blood pressure of 173/104 mm Hg. Propranolol 60 mg/day was no better than placebo. A minor reduction in lying diastolic pressure was seen within four hours of a single oral dose of 80 mg of propranolol.
The reasons for using a double-blind crossover within-patient design have been outlined elsewhere.1 2 There is also individual variation in the handling of oral propranolol,3 and a withinpatient design is therefore particularly appropriate. The doses of propranolol chosen were arbitrary and in the lower ranges because there was a surprising lack of careful work on the response of patients to different doses of propranolol, and some workers may have proceeded to higher doses without waiting long enough to observe the effect of lower doses. We were reluctant to carry out the study using higher doses because the design determined that six previously untreated patients would receive a starting dose of propranolol of 240 mg/day and would be switched after one month directly to placebo. Indeed this was one reason for observing the effects of the 80-mg single oral test dose while the patients were in the ward under supervision. Propranolol is reputed not to have an immediate lowering effect on blood pressure and we were surprised to find a reduction over the four-hour period with the higher dose. This suggests that the use of low starting doses of propranolol leads to a slower onset of hypotensive action.
Doubling the dose of propranolol in the outpatient study above 120 mg/day did not cause a statistically significant increase in the hypotensive effect. We have observed this lack of an increase in effect in a group of patients given the cardioselective beta-blocker atenolol, and the lack of an increase in effect has also been shown by others with oxprenolol.4 Within-patient comparisons of the doses used in this study with higher dosesfor example, 360 mg-4 g/day-would clearly be of interest.
Introduction
Phosphate Case 1
A 16-year-old man with familial renal-retinal dystrophy7 presented in rcnal failure in July 1972. The serum calcium concentration was (7 0 mg/100 ml), and serum alkaline phosphatase 166 IU/l. Bone x-ray films showed a bone age of 11 years but were otherwise normal. Bone biopsy showed osteomalacia with an osteoid index8 of 5 0. Treatment with regular haemodialysis was started in July 1972, and oral aluminium hydroxide (2-4 g daily) was started four months later. The patient received phenytoin in doses ranging from 200-300 mg/day from July 1972 to May 1974. Serum calcium levels returned to normal within three months of the start of dialysis, while predialysis serum inorganic phosphate levels between October 1973 and May 1974 ranged from 0-55 to 1-2 mmol/l (1-7-3-6 mg/100 ml) (mean 0-71 mmol/l (2-2 mg/100 ml) ). Serum alkaline phosphatase gradually rose to 1150 IU/1. Serum immunoreactive parathyroid hormone levels ranged from 0-6-2-4~ig/l. On 9 May 1974 he was admitted with severe pain in the limbs and inability to walk. Pelvic x-ray examination showed Looser zones, and a repeat bone biopsy showed severe osteomalacia with an osteoid index of 30.
The patient was treated with 2-5 mg dihydrotachysterol per day, and aluminium hydroxide treatment was discontinued. These measures were followed by complete symptomatic relief in six weeks. Predialysis serum inorganic phosphate levels rose to 1-3 mmol/l (4-0 mg/100 ml) or greater. Serum alkaline phosphatase activities initially rose to 2500 IU/l and fell to 200 IU/l three months later. The patient resumed aluminium hydroxide treatment and continued to take dihydrotachysterol (0 625 mg/day). 0-9 mmol/l (2-8 mg/100 ml), and the mean predialysis calcium level was 2-45 mmol/l (9-8 mg/100 ml). Serum alkaline phosphatase gradually rose to 923 IU/l. The mean predialysis serum immunoreactive parathyroid hormone level was 4-2 ,ig/l.
In May 1974 he was admitted because of generalised muscle weakness and pain in the limbs which were so severe that he was unable to walk. Skeletal x-ray films showed rachitic changes, and a repeat bone biopsy showed an osteoid index of about 30. Aluminium hydroxide was withdrawn and dihydrotachysterol (0-625 mg/day) was prescribed.
